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ABSTRACT: Magainin and PGLa are 23- and 21-residue peptides isolated from the skin of the African clawed 
frog Xenopus lueuis. They protect the frog from infection and exhibit a broad-spectrum antimicrobial activity 
in vitro. The  mechanism of this activity involves the interaction of magainin with microbial membranes. 
We have measured the secondary structure and membrane-perturbing ability of these peptides to obtain 
information about this mechanism. Our results show that mgn2a forms a helix with an average length of 
less than 20 A upon binding to liposomes. A t  high concentrations (50 mg/mL) mgn2a spontaneously 
solubilizes phosphatidylcholine liposomes a t  temperatures above the gel-liquid-crystalline phase transition. 
Mgn2a appears to bind to the surface of liposomes made of negatively charged lipids without spontaneously 
penetrating the bilayer. Finally, mgn2a and PGLa interact together with liposomes in a synergistic way 
that enhances the helix content of one or both of the peptides and allows the peptides to more easily penetrate 
the bilayer. PGLa mixed with a small nonperturbing amount of magainin 2 amide is 25-43 times as potent 
as PGLa alone a t  inducing the release of carboxyfluorescein from liposomes. The  results suggest that the 
mechanism of antimicrobial activity does not involve a channel formed by transmembrane helical peptides. 
M a g a i n i n ,  also known as PGSI (Giovannini et al., 1987; 
Terry et al., 1988), is a family of 23-residue peptides that are 
secreted from the skin of the African clawed frog. They 
protect the frog from wound infection and exhibit a broad- 
spectrum antimicrobial activity in vitro (Zasloff, 1987; Zasloff 
et al., 1988). On a molar basis this activity is as potent as 
tetracycline against some organisms. 
PGLa, another antimicrobial peptide isolated from frog skin, 
has an antimicrobial activity that is comparable to that of 
magainin 2 (Soravia et al., 1988), but these peptides have little 
sequence homology. The sequences of magainin 1 amide 
(mgnla), magainin 2 amide (mgn2a), and PGLa are (Giov- 
annini et al., 1987) 
mgn 1 a: Gly-He-GI y-Lys-Phe-Leu-His-Ser- Ala-Gly-Lys- 
Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-Met-Lys-Ser-NH2 
mgn2a: Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys- 
Phe-GI y-Lys-Ala-Phe-Val-GI y-Glu-He- Met-Asn-Ser-NH2 
PGLa: Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala- 
Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu-NH2 
These peptides are positively charged and can form extremely 
amphiphilic helices about 30 A in length. These features are 
common to polypeptides that bind to and effect the permea- 
bility of lipid bilayers (Sparrow & Goto, 1982; DeGrado et 
al., 1981; Green et al., 1987), and it has been suggested that 
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magainins might act as detergents or transmembrane helical 
channel formers (Zasloff, 1987; Guy & Raghunathan, 1988). 
Indeed, measurements using a single channel conductance 
apparatus indicate that magainin forms a voltage-dependent 
channel in artificial membranes (Cruciani et al., 1988). 
Magainin 2 amide causes membrane depolarization in Es- 
cherichia coli cells and cytochrome oxidase liposomes (JuretiE 
et al., 1989), and magainin 2 amide and PGLa dissipate the 
electric potential across energy-transducing membranes, un- 
coupling respiration from other free-energy-requiring processes 
(Westerhoff et al., 1989a,b). The effect of mgnl on the 
permeability of liposomes has been investigated by Matsuzaki 
et al. (1989), who observe that mgnl induces leakage of calcein 
out of negatively charged vesicles and binds to bovine brain 
phosphatidylserine according to the Langmuir isotherm with 
a binding constant of 43.8 X 105/M and that leakage appears 
to occur at a binding number of 0.03 per lipid molecule; their 
CD measurements indicate that mgnl has an unordered 
structure in solution and that it forms a 57% a-helix upon 
binding to PS. 
CD of peptide in 40% trifluoroethanol (TFE; mixtures of 
water and TFE are used as a membrane mimetic solvent) 
indicates 24% a-helix (Chen et al., 1988), and NMR of 30 
mg/mL mgn2a in 25% TFE indicates some a-helix (Marion 
et al., 1988). Raman measurements show that liposome-bound 
mgn2a contains as much as 71% helix (Williams et al., 
1988a,b). These studies also indicate that magainin 2 amide 
Abbreviations: mgnl, magainin 1; mgn2, magainin 2; mgn2a and 
magainin 2a, magainin 2 amide; PGS, peptide beginning with glycine and 
ending with serine; PGLa, peptide beginning with glycine and ending with 
leucine amide; SDS, sodium dodecyl sulfate; DPPG, L-a-dipalmitoyl- 
phosphatidylglycerol; DPPC, dipalmitoylphosphatidylcholine; PS, bovine 
brain phosphatidylserine; PC, bovine brain phosphatidylcholine; PE, 
bovine brain phosphatidylethanolamine; SUV, small unilamellar vesicle; 
MLV, multilamellar vesicle; Gdn-HCI, guanidine hydrochloride; TFE, 
2,2,2-trifluoroethanol; CF, 6-carboxyfluorescein. 
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contains 0% helical structure in aqueous solutions. 
To ascertain the effect of secondary structure on antimi- 
crobial activity, Chen et al. (1  988) prepared a series of ma- 
gainin analogues with varying propensities to form helix and 
determined the dose-response to these compounds in biological 
assays. By substituting residues 9, 13, and 18 with D-alanines, 
they prepared a derivative that is unlikely to form a helix. By 
substituting glycines 13 and 18 with L-alanine, they increased 
the helix-forming tendency of the peptide. The results showed 
a positive correlation between antimicrobial activity and 
tendency to form helix in TFE. Raman measurements of 
secondary structure of these analogues bound to liposomes also 
show this correlation (Williams et al., 1988~) .  Omission of 
glycine 18 in mgn2a does not increase antimicrobial activity, 
but does increase hemolytic activity (Cuervo et al., 1988). 
In  this paper we survey the secondary structure and mem- 
brane-perturbing characteristics of mgn2a and PGLa bound 
to liposomes under a variety of conditions. We measure the 
effect of mgn2a binding on the structure of liposome acyl 
chains, and we quantitate the membrane-perturbing kinetics 
of mgn2a and PGLa by measuring C F  release from CF-loaded 
liposomes. Our results show that mgn2a forms an a-helix with 
an average length of less than 20 A upon binding to liposomes. 
At high concentrations (50 mg/mL) mgn2a spontaneously 
solubilizes phosphatidylcholine liposomes at temperatures 
above the gel-liquid-crystalline phase transition. Mgn2a ap- 
pears to bind to the surface of liposomes made of negatively 
charged lipids without spontaneously penetrating the bilayer. 
Finally, mgn2a and PGLa interact together with liposomes 
in a synergistic way that enhances the helix content of one or 
both of the peptides and facilitates the peptide's penetration 
into the bilayer. 
MATERIALS A N D  METHODS 
Materials. The purification of magainin 2a and PGLa is 
described elsewhere (Zasloff, 1987). Melittin was obtained 
from Sigma and further purified by reversed-phase high- 
pressure liquid chromatography on a Waters 8MBC18 10 
Radial-Pak C- 18 cartridge. Initial gradient conditions were 
70% trifluoroacetic acid and 30% acetonitrile, changing to 40% 
trifluoroacetic acid and 60% acetonitrile over 30 min at a flow 
rate of 2 mL/min. Synthetic DPPG and DPPC and bovine 
brain PC, PE, and PS were obtained from Avanti Polar Lipids 
Inc., Pelham AL. 
Liposome Preparation. DPPG and DPPC in multilamellar 
vesicles (MLVs) were prepared as follows: A solution of lipid 
in chloroform was evaporated to dryness in a test tube under 
a stream of nitrogen. Then 0.14 M KCl was added to bring 
the final lipid concentration to 10-50 mg/mL. This dispersion 
was subjected to 10 cycles of vortexing, freezing in dry ice- 
acetone, and thawing to 50 OC. Lipid-bound and unbound 
peptide could be rapidly and completely separated by pelleting 
the vesicles in a microhematocrit centrifuge. 
Small unilamellar vesicles (SUVs) for C F  release experi- 
ments were prepared as follows: 5 mg/mL phospholipid ( 2 5 3  
PC:PE:PS) was evaporated to dryness in a test tube under a 
stream of nitrogen and sonicated in a solution of 0.5 M NaCl, 
10 mM Pipes, pH 7.0, and 80 mM C F  (Kodak) by using a 
Heat Systems-Ultrasonics Inc. Model W 185F sonicator with 
a cup-horn bath at maximum power for 20 min. These CF- 
loaded vesicles were separated from free C F  by elution through 
a 2-mL Sephadex G25 column with 0.5 M NaCl and 10 mM 
Pipes, pH 7.0. The void volume was collected and diluted to 
a lipid concentration of 2.5 mg/mL for storage. These vesicles 
were diluted to a concentration of 50 pg/mL lipid in 0.5 M 
NaCl and 10 mM Pipes. Aliquots (1 mL) of this dispersion 
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were used to measure C F  release. Increase in fluorescence 
was measured at  520 nm with 470-nm excitation (Weinstein 
et al., 1984); 100% fluorescence was determined by the ad- 
dition of 20 pL of 10% Triton X-100, to a final concentration 
of 0.5% Triton. 
Magainin 2 amide, PGLa, and melittin solutions were 
prepared to 5% w/w in 0.14 M NaCl, and the pH values of 
these solutions were adjusted to 7.4 with 0.1 M NaOH. The 
formula weights (including neutralizing salts) of mgn2a and 
PGLa were taken to be 2701 and 2146, respectively. Pep- 
tide-lipid complexes were prepared by mixing 10 pL of peptide 
solution with 10 pL of lipid suspension. Samples were pelleted 
in melting point capillary tubes with a Damon/IEC micro- 
hematocrit centrifuge for 15 min to concentrate the lipid- 
peptide complex and to exclude supernatant containing un- 
bound peptide. Spectra were collected of the pellets and su- 
pernatants of these samples. The pellets were then resuspended 
in their respective supernatants and heated at 50 "C; the 
magainin-DPPG sample was heated for 30 min, and the 
melittin-DPPG sample was heated for 10 min. After 10 min 
of heating, the milklike lipid dispersion in the melittin sample 
became mostly clear, indicating that large liposomes had been 
broken into much smaller particles. Spectra were collected 
again. Another 20 pL of DPPG suspension was added to the 
magainin and melittin, the pellets were resuspended, the 
samples were heated at 50 "C for 30 min, and spectra were 
collected again. 
Raman Spectroscopy. Raman instrumentation is described 
elsewhere (Williams, 1986). The laser was operated at 514.5 
nm with typically 200 mW of light power focused at the 
sample to a beam with a diameter of about 0.5 mm for pre- 
cipitates of lipid and peptide, and a diameter of about 0.1 mm 
for solutions and supernatants. The thermostated sample 
holder was held at  14 "C. 
Raman spectra of peptides were analyzed for secondary 
structure information according to the method of Williams 
(1983, 1986). Briefly, fractions of helix, &strand, reverse turn, 
and unfolded structure are estimated from the Raman spec- 
trum of the peptide by fitting the amide I spectrum with a 
linear combination of amide I spectra of proteins whose 
structures are known by X-ray diffraction. The secondary 
structure is then calculated as a sum of fractions of the ref- 
erence proteins. The procedure used here differs from the one 
described (Williams, 1986) in that the spectrum of lysozyme 
in 4 M guanidine hydrochloride (Gdn-HC1) was added to the 
set of reference spectra. This amide I spectrum is identical 
with the spectra of several other proteins in unfolding con- 
centrations of Gdn-HC1 and is taken here to represent the 
spectrum of a protein or peptide that is unfolded. 
Subtraction of the spectrum of water from spectra of pep- 
tide-lipid mixtures cannot be performed by the method de- 
scribed earlier (Williams, 1986) because of the strong phos- 
pholipid ester C=O stretching band between 1700 and 1780 
cm-I. The correct amount of water spectrum to be subtracted 
was determined as follows: After collection of Raman spectra 
of the pelleted vesicles, the pellet was evaporated to dryness 
under a stream of nitrogen and the Raman spectrum of the 
dry pellet collected. (This drying treatment does not com- 
pletely dehydrate liposome samples.) Water subtraction was 
adjusted to bring the water-subtracted spectrum into con- 
gruence with the dehydrated sample spectrum. These spectra 
were generally identical. 
We define here a new expression for a lipid order parameter 
(LOP) to quantitate the effect of peptides on the structure of 
phospholipids 
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I1 128,GP sample I1 125,LCP reference 
I1095.GP sample 11095,LCP reference 
- 
LOP = 
I1 128,GP reference I1 I25,LCP reference 
I1095,GP reference z1095,LCP reference 
- 
where IIlzs is the Raman intensity at 1128 cm-I and the G P  
reference is the spectrum of gel-phase (GP) multilamellar lipid 
vesicles (MLVs) prepared by freezing and thawing in normal 
saline. The spectrum is measured at  a temperature (14 OC 
in this case) well below both the main and premelting gel to 
liquid-crystalline phase (LCP) transitions. The LCP reference 
is the spectrum of the same vesicles measured at a temperature 
(50 OC for DPPG) well above the main GP to LCP transition. 
The intensity at 1095 cm-I is an iso-Raman point for the 
melting transition (Gaber et al., 1978) and is used to normalize 
each spectrum. 
This parameter (LOP) indicates the intensity of the 1128- 
cm-l band (which is due to coupled vibrations from adjacent 
trans bonds) relative to its intensity in nearly all trans struc- 
tures (solid), where LOP = 1, and all melted structures, where 
LOP = 0. This band is generally accepted to be the most 
reliable indicator of this structure change. We cannot presently 
explain the changes observed in the 1064-cm-' band. The 
1 128-cm-l band does not indicate the number of gauche and 
trans bonds, since the intensity of these bands is probably not 
a linear function of conformation. Nor does it indicate to what 
extent the peptide is or is not inserted into the acyl-chain region 
of the bilayer. It does, however, give a relative indication of 
how peptide binding disrupts (or orders) the lipid acyl-chain 
structure. 
Analysis of CF Release. C F  fluorescence data were con- 
verted to percent C F  remaining in vesicles by the expression 
%CF,,, = ( 1  - F/FT)/Qv,  where F is fluorescence measured 
at  any time, FT is total C F  fluorescence after disruption of 
vesicles with Triton, and Qv is a correction for the residual 
fluorescence of dye in the vesicles (Weinstein et al., 1984). 
To quantitate differences between the membrane-perturbing 
abilities of PGLa and a mixture of PGLa and mgn2a, a 
double-exponential fit was applied to the C F  release data by 
using the SAAM (Simulation, Analysis And Modeling) program 
(Berman & Weiss, 1978). C F  remaining in liposomes was 
expressed as CFrem(%) = Aeklr + BekZt, where A and B are 
proportionality coefficients with A + B = 100, t is time, and 
k l  and k2 are pseudo-first-order rate constants where kl = 
K,[peptide] + C and k2 = KJpeptide] + C. Constants for 
liposome permeability, K1 and K2, were estimated as the slope 
of the linear regression line through kl and k2 plotted as a 
function of peptide concentration (Figure 5). For example, 
for PGLa alone, K, = Ak,/A[PGLa] = 0.16 (s.M)-'. There 
are a number of ways to analyze this type of kinetic data 
(Bentz et al., 1988; Bentz & Nir, 1981). We have chosen the 
presentation described here to emphasize the differences be- 
tween the effects of each isolated peptide and a mixture of 
mgn2a and PGLa. 
RESULTS AND DISCUSSION 
a-Helical Peptides. Figure 1 shows the Raman amide I 
spectra of magainin 2 amide (mgn2a) compared with spectra 
of other peptides and proteins with known structures. One 
of these structures is that of melittin, a 26-residue amphipathic 
peptide that is 96% helix in the crystal (Terwilliger et al., 
1982). We compare spectra of mgn2a to those of melittin 
because melittin is similar in some ways to mgn2a in size, 
charge, and amphipathicity and because much is already 
Williams et a]. 
Table I:  Secondary Structure Content" (Percent) in Magainin 2a 
and PGLa from the Raman Amide I SDectrum 
structure type 
peptide helix &strand turn unfolded 
mgn2a, 0.14 M NaCI, pH 7.4 
mgn2a, water, pH 7.1 
mgn2a, dilute HCI, pH 3.2 
mgn2a, 5.8 M GdmHCI 
mgn2a precipitate in saline 
PGLa, 0.14 M NaCI, pH 7.4 
PGLa, water, pH 7.0 
PGLa, dilute HCI, pH 3.2 
PGLa, 5.5 M GdneHCI, pH 7.3 
PGLa ppt in 0.14 M NaCI, pH 7.4 
mgn2a:DPPC 1:l  (1:3.7), pH 8.5, 
mgn2a:DPPC 1:3 (1:ll  by mole), 
mgn2a:DPPC 1:16 (1:59), 50 OC 
mgn2a:PGLa:DPPC l : l : l ,  pH 7.4 
mgn2a:PGLa:DPPC 1 : 1 :2, pH 7.4 
mgn2a:PGLa:DPPC l : l : l ,  pH 3.6 
mgn2a:DPPG 1 : 1 ,  pH 7.4 
PGLa:DPPG 1 : 1 ,  pH 7.0 
mgn2a:DPPG 1 : 1 ,  pH 3.6 
PGLa:DPPG I : ] ,  pH 3.6 
mgn2a:PGLa:DPPG 1:1:2, pH 3.6 
mgn2a:PGLa:DPPG l : l : l ,  pH 3.5 
mgn2a:PGLa 1 : 1 ,  water, pH 7.1 
mgn2a:PGLa 1:1, dilute HCI, 
mgn2a + PGLa, sum of data, 
mgn2a:DMPC 1:4, pH 7.3, supt 
mgn2a:DMPC 1:4, pH 7.3, pellet 
PGLa:DMPC 1 : 1 ,  water, pH 7.0 
mgn2a:SDS 1 : 1 ,  post 50 "C 
mgn2a in 20% TFE 
melittin crystalsC 
melittin, 0.14 M NaCI, pH 7.4 
me1ittin:DPPG 
ribonuclease S-peptide:DPPG 1 : 1 
standard deviations" 
suptb 
pH 3.6 
pH 3.2 
pH 3.2 
0 
0 
0 
0 
45 
6 
1 
0 
0 
3 
47 
46 
35 
30 
37 
14 
58 
3 
45 
27 
53 
47 
0 
0 
0 
59 
46 
42 
47 
0 
84 
82 
73 
0 
f 5  
3 1 96 
0 0 100 
0 0 101 
0 0 99 
6 18 19 
21 8 59 
0 63 21 
6 2 90 
19 6 71 
0 69 24 
19 20 2 
19 22 0 
31 23 0 
15 12 34 
26 12 15 
8 5 70 
14 20 0 
67 23 0 
19 22 0 
45 25 0 
18 22 0 
20 23 0 
2 1 97 
4 1 94 
0 0 100 
12 18 0 
20 23 0 
15 13 19 
0 20 23 
30 10 54 
4 7 0 
5 7 0 
9 10 0 
2 91 7 
f 4  f 2  
"The sum of structure contents was 100 f 2%. Undefined structure 
content, the remainder from loo%, is not shown. Standard deviations 
represent differences between Raman and X-ray diffraction measure- 
ments for the reference proteins. b"supt" indicates that liposomes were 
dissolved by peptide and that the spectrum was taken of the clear su- 
pernatant above pelleted material. Melittin, having a 96% helical 
crystal structure, was excluded from the reference set for this calcula- 
tion. Melittin was not excluded from the reference set for estimates of 
its structure in DPPG and 0.14 M NaCI. 
known about the structure of melittin and its interaction with 
lipid bilayers (Brown et al., 1982; Bernard et al., 1982; 
Georghiou et al., 1982; DeGrado et al., 1982; Levin et al., 
1982). In addition, there is an error in the Raman estimate 
of helix content in melittin that may also exist in the estimate 
for helical mgn2a samples; the Raman estimate of helix 
content in melittin crystals (Table I )  is 8495, which is 12% 
(three residues) below the X-ray diffraction structure. This 
difference may be due to end effects, since the ends of helical 
segments have an amide I spectrum different from that of 
residues in the middle of a helical segment (Williams & 
Dunker, 1981). We suspect that helical residues that are on 
the very ends of a peptide (as they are in melittin) will have 
yet a different amide I spectrum. Our estimate of helix content 
for mgn2a in DPPG here is 58% (Table I). If we assume that 
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Frequency shift, cm-I 
FIGURE 1 : Amide 1 Raman spectrum of magainin 2 amide bound to 
DPPG liposomes, compared with reference spectra of peptides and 
proteins with known structures. Mgn2a:DPPG 1:l  (ratios are by 
weight) in saline, pH 7.4 (heavy dotted line); melittin crystals, >96% 
helix (light dotted line); me1ittin:DPPG 1:1 in saline, pH 7.4 (solid 
line); melittin in saline, pH 7.4 (line with one dot); hemerythrin, 80% 
helix in a four-helix bundle (line with one dash); concanavalin A 
crystals, 65% @-sheet-2% helix (dashed line); erabutoxin, 62%.p- 
sheet-0% helix (line with three dots); unfolded ribonuclease S-peptide 
(thin line with two dots); lysozyme unfolded in 4 M guanidine hy- 
drochloride (line with two dashes). 
this estimate is also 12% low, we can set an upper limit of 70% 
helix for the average helix content in this sample of mgn2a. 
This corresponds to 16 residues, 24 8, in an a-helix, which is 
not long enough to span a lipid bilayer. 
The spectrum of a helical peptide bound to lipid vesicles or 
in solutions may be different from the spectrum of the same 
peptide, with the same structure, in a crystal. To investigate 
this possibility in the context of helical peptides that may form 
bundles that span lipid bilayers, we collected Raman spectra 
of melittin bound to lipid vesicles and in solution. As can be 
seen in Figure 1, the differences between the spectra of crystal 
and lipid-bound structures are relatively small. 
We show in Figure 1 the spectra of proteins and peptides 
that illustrate the validity of using a database of Raman 
spectra of relatively large proteins for an analysis of the spectra 
of a 23-residue peptide. Erabutoxin has 62 residues, 3 di- 
sulfides, and is 50% p-sheet-0% helix (Low et al., 1976). 
Concanavalin A has 237 residues, contains no cysteines, and 
is 51% p-sheet-2% helix (Reeke et al., 1975). The secondary 
structure contents and the amide I spectra of these proteins 
are nearly identical. The spectrum of hemerythrin, a 113- 
residue 80% helical protein, is similar to the spectra of melittin, 
differing only in the way expected for two helical proteins that 
differ in helix content. The amide I spectrum of the 24-residue 
ribonuclease S-peptide in its unfolded structure (Kim et ai., 
1982) is nearly identical with the spectrum of lysozyme in 
guanidine hydrochloride, indicating that it is valid to use this 
spectrum of lysozyme as a reference for unfolded structure. 
There is no indication that secondary structure in a 20-residue 
peptide will have an amide I spectrum that is different from 
the same secondary structure in a large protein. 
Interaction with Liposomes. The interactions of mgn2a with 
negatively charged DPPG and with zwitterionic DPPC and 
DMPC vesicles are different. When mgn2a was added to 
dispersions of DPPG MLVs, the vesicles rapidly flocculated. 
The flocculated appearance of these samples remained un- 
changed when they were heated to a temperature above the 
gel to liquid-crystalline phase transition. These aggregated 
vesicle-peptide complexes were easily separated from free 
mgn2a that might be left in the solution. We observed a 
marked change in  the light scattering from lipid dispersions 
upon addition of peptides. Since we have no quantitative 
light-scattering measurements from these samples, some of 
them only 5 pL, we describe this change qualitatively here by 
comparing the appearance of the dispersion to milk, where light 
Frequency shift, cm-' 
FIGURE 2: Amide I Raman spectrum of magainin 2 amide bound to 
liposomes and in solution. The spectra of melittin crystals (dotted 
line) and of unfolded ribonuclease S-peptide (thin line with two dots) 
are shown in both panels as references. (A) Mgn2a:DPPG 1:1 (ratios 
are by weight) in saline, pH 7.4 (solid line); mgn2a:DMPC 1:4 in 
water, pH 7.3 (line with one dot); mgn2a 200 mg/mL in 5.8 M 
Gdn-HCI, pH 7 (line with one dash); mgn2a precipitated at 14 OC 
in saline, pH 7.4 (dashed line); mgn2a in saline solution at 22 OC, 
pH 7.4 (line with three dots). (B) Mgn2a:DPPC 1:3 in saline, pH 
3.6, after 50 OC, 15 min, clear dispersion (line with three dots); 
mgn2a:DPPC 1:1 pH 8.5, after 50 "C, 30 s, clear dispersion (line with 
one dot); mgn2a:SDS 1:1.5 after 50 OC, 30 s, clear solution (solid 
line); mgn2a in 20% TFE in water (line with one dash); concanavalin 
A crystals, a 55% P-sheet-2% helix reference protein (dashed line). 
scattering is very high, before addition of peptide, and as 
becoming clear (as water) after addition. When mgn2a was 
added to the milky dispersions of DPPC and DMPC, no 
change was observed. However, when these samples were 
heated to a temperature above the gel to liquid-crystalline 
phase transition, they immediately became clear, indicating 
that the liposomes were solubilized into much smaller particles. 
The interactions of melittin with both DPPG and DPPC were 
more similar; the milky vesicle dispersion became nearly clear 
in both cases, even to some extent at temperatures below the 
gel to liquid-crystalline phase transitions. They were not as 
clear as those obtained from mgn2a in DPPC and DMPC. 
The structure of mgn2a changes upon binding to lipid 
vesicles from a mostly unfolded structure in aqueous solution 
to a helical structure in the peptide-lipid complex (Figure 2; 
Table I). The amide I spectra of mgn2a in aqueous solutions 
or in Gdn-HC1 are to some extent different from our reference 
spectrum for unfolded peptide structure (Figure 2A). This 
may indicate that, while being mostly unfolded, the peptide 
has some preferred turn structure in solution, and there may 
be some artifact from the subtraction of the Gdn.HC1 spec- 
trum. The structure of mgn2a appears to be similar bound 
to DPPG and DMPC (Figure 2A; Table I), but helix content 
is lower in DPPC by more than 10% (two residues). The 
mgn2a structures in the form precipitated from aqueous so- 
lution in the cold (Figure 2A) and in DPPC (Figure 2B) are 
similar. 
The ratio of lipid to peptide may affect peptide structure, 
especially in mixtures of mgn2a and DPPC where vesicles are 
solubilized by the peptide and free peptide cannot be separated 
from the peptide-lipid complex. To test this possibility, sam- 
ples of Mgn2a-DPPC were measured at mole ratios of 1:3.7, 
1:11, and 159. At the 159  ratio the dispersion retained much 
of its turbid appearance after the addition of peptide and 
incubation at 50 "C. The mgn2a structure did not change 
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FIGURE 3: Raman spectra of pellets of lipid LUVs in PBS (unless 
otherwise indicated) with and without bound peptide, showing the 
lipid acyl-chain C-C stretching region, and in particular the band 
at 1 1  28 cm-I, that indicates (nonlinearly) the extent of trans-gauche 
isomerization. The top frame shows spectra of DPPG well below the 
gel to liquid-crystalline phase transition at 14 OC (thin solid line) and 
of DPPG just above this transition, at 45 OC (thin dashed line); 
mgn2a:DPPG 1 : l  at 14 OC, pH 7.4 (the band at 1032 is from the 
mgn2a phenylalanines) (line with one dot); mgn2a:DPPG 1:l at 14 
OC, pH 7.4, after 30 min at 50 OC (dotted line); me1ittin:DPPG 1:l 
at 14 “C, pH 7.4 (line with one dash); melittin:DPPG 1:l  at 14 OC, 
pH 7.4, after 10 min at 50 OC (line with two dashes); ribonuclease 
S-peptide:DPPG 1 : l  at 14 OC, pH 7.4, after 30 min at 50 OC (this 
spectrum is the same before the 50 O C  treatment) showing that 
ribonuclease S-peptide in an unfolded structure disrupts the lipid 
acyl-chain structure more than mgn2a (thin line with three dots). 
(Bottom frame) DPPC at 14 OC (thin solid line); DPPC at 45 OC 
(thin dashed line); mgn2a:DPPC 1 : l  at 14 OC, pH 3.7, showing that 
mgn2a does not copellet with DPPC liposomes (line with one dot); 
mgn2a:DPPC 1:l at 14 OC, pH 8.5, after 10 min at 50 OC (liposomes 
are dissolved by this treatment; this spectrum was taken of a clear 
solution) (dotted line); me1ittin:DPPC 1:l at 14 OC, pH 5.3 (liposomes 
are dissolved by this treatment, but not to a clear solution as with 
mgn2a; this spectrum was taken of a translucent dispersion) (line with 
one dash); me1ittin:DPPC 1:l at 14 OC, pH 5.3, after 10 min at 50 
OC showing that heating this mixture to above the gel to liquid- 
crystalline phase transition does not induce further changes in the 
lipid structure (line with two dashes). Ratios are by weight. 
significantly as the amount of DPPC was increased (Figure 
2B; Table I ) .  Spectra collected a t  50 OC were not significantly 
different from spectra collected a t  14 OC, as was the case with 
spectra collected from samples a t  pH 7-9 and a t  pH 3-4. 
Membrane Mimetic Solvents. Spectra of mgn2a in mem- 
brane mimetic environments, mixed with SDS and in 20% 
trifluoroethanol (TFE), are significantly different from spectra 
of the peptide mixed with lipid vesicles (Figure 2B). These 
results indicate that SDS and TFE may not be good model 
solvents for magainins in a membrane environment. Other 
peptides have shown “distinctly different conformations in 
membranes and in organic solvents” (Wallace, 1983). Raman 
measurements of magainin 2 amide at 50 mg/mL in 20% TFE 
(Table 11) appear to be in conflict with the N M R  results 
(Marion et al., 1988) that indicate mgn2a is helical in dilute 
TFE solutions. However, the N M R  measurements were made 
of solutions that contained higher concentrations of TFE. Our 
results from magainins in TFE will be reported more fully 
elsewhere. 
Lipid Acyl-Chain Disorder. The extent of lipid acyl-chain 
disorder induced by peptide binding to DPPG and DPPC was 
measured from the Raman spectrum in the C-C stretching 
region (Figure 3) and quantitated in terms of our LOP (Table 
Table 11: Lipid Order Parameters from the C-C Stretching Raman 
Spectra of Peptide-Lipid Complexes 
complex pre 50 O C ”  post 50 OC 
mgn2a:DPPG 1:1, pH 7.4 0.73 0.59 
me1ittin:DPPG 1:1 0.65 0.23 
ribonuclease S-peptide:DPPG 1 : 1 0.46 0.36 
mgn2a:DPPC 1: l  (1:3.7), pH 8.5, suptb 1.00 0.83 
me1ittin:DPPC 1:l 0.90 0.71 
‘Samples were measured before and after the sample was incubated 
at 50 OC for 10-30 min. b”supt” indicates that liposomes were dis- 
solved by peptide and that the spectrum was taken of the clear super- 
natant above pelleted material. 
Frequency shift, cm-’ 
FIGURE 4: Amide I Raman spectra of PGLa and mixtures of PGLa 
and mgn2a bound to liposomes and in solution. The spectra of melittin 
crystals (dotted line) and unfolded ribonuclease S peptide (line with 
two dots) are shown in both frames as references. (A) PGLa pre- 
cipitate in 0.14 M NaC1, pH 7.4 (solid line); PGLa:DPPG 1:l in dilute 
HCI, pH 3.6 (line with one dot); PGLa in water pH 7.0 (line with 
one dash); PGLa in water, pH 3.2 (line with three dots); PGLa in 
0.14 M NaCI, pH 7.4 (dashed line); PGLa:DMPC 1:1, pH 7.0 (line 
with two dashes). (B) Mgn2a:PGLa:DPPG 1:1:2, pellet of vesicles 
(solid line); arithmetic sum of the spectra of mgn2a:DPPG 1:l and 
PGLa:DPPG 1:l (line with three dots); mgn2a:PGLa 1:l in water, 
pH 7.1 (line dot); arithmetic sum of spectra of mgn2a in saline, pH 
7.4, and PGLa in water, pH 7.0 (line all dash). 
11). The acyl chains of DPPG appear to be slightly more 
disordered (contain more gauche conformations) after incu- 
bation with mgn2a a t  50 “C, but the spectrum between 1000 
and 1030 cm-I (not shown) shows an increase in the intensity 
of the 1003-cm-’ mgn2a phenylalanine band that is propor- 
tional to the decrease in the intensity of the DPPG bands upon 
heating. This indicates that this increase in acyl-chain disorder 
is probably due to an increase in the amount of mgn2a bound 
to the DPPG vesicles and not to a change in structure. Melittin 
is more disruptive than mgn2a and completely disorders the 
acyl chains after incubation a t  50 OC, possibly by forming 
peptide-lipid micelles. 
DPPC appears to be much less disordered by mgn2a or 
melittin than DPPG, even in samples of Mgn2a-DPPC com- 
plex that have turned clear after heating a t  50 OC. These 
results, combined with our qualitative observation that mgn2a 
solubilizes DPPC liposomes and greatly reduces their light 
scattering, may indicate that the Mgn2a-DPPC complex 
formed after heating is a disk-shaped micelle in which the lipids 
can form a planar bilayer within a ring of peptide molecules. 
A similar annular protein-bilayer disk model has been proposed 
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Upon binding to DMPC, the structure of PGLa becomes a 
42 f 5% helical. 
Synergistic Interaction of Mgn2a and PGLu. PGLa is only 
27 f 5% helix when bound to DPPG, but an equimolar 
mixture of PGLa and mgn2a appears to contain significantly 
more helix when bound to DPPG than the average of the 
separate peptides (Table I; Figure 4B). Equimolar mixtures 
of PGLa and mgn2a in water do not interact in this way to 
form secondary structure. 
One of the most striking features of these peptides is that 
they appear to act synergistically. To measure the mem- 
brane-perturbing activity of mgn2a and PGLa at physiolog- 
ically active concentrations, we measured the release of 6- 
carboxyfluorescein (CF) from liposomes as a function of 
peptide concentration and calculated constants related to 
membrane-perturbing activity (Figure 5 ) .  Mgn2a does not 
release C F  at 10 pg/mL (3.7 pM). This is consistent with 
the low hemolytic activity of mgn2a. PGLa does release C F  
at relatively low concentrations. However, in the presence of 
10 pg/mL mgn2a, PGLa is dramatically more active. For 
PGLa alone, K ,  and K2 = 0.16 and 0.007 (s.M)-', respectively. 
For PGLa with 3.7 pM mgn2a, K ,  and K2 = 4.0 and 0.3 
(s.M)-', respectively. The change in K 1  and K2 caused by the 
presence of an amount of mgn2a that by itself does not cause 
permeability is 25- and 43-fold, respectively. These results 
suggest that the interaction of these two antimicrobial peptides 
at the membrane surface produces a structure change in one 
or both of the peptides that potentiates the antibiotic activity. 
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FIGURE 5 :  Intensity of CF fluorescence after addition of antimicrobial 
peptide to CF loaded liposomes. Numbers to the right, next to each 
curve, indicate final concentrations of peptide in micrograms per 
milliliter, where IO pg/mL PGLa is 4.66 pM and 10 wg/mL mgn2a 
is 3.7 pM. (Top) Magainin 2a was added at time 0. (Middle) PGLa 
was added at time 0. (Inset) Pseudo-first-order rate constants (see 
Materials and Methods) plotted as a function of PGLa concentration. 
Solid symbols represent k , ,  and open symbols represent k2. PGLa 
k ,  (open triangle); PGLa k2 (solid box); mixture (3.7 gM mgn2a plus 
indicated amount of PGLa) k ,  (solid circle); mixture k2 (open circle). 
(Bottom) Magainin 2a was added to liposomes to a final concentration 
of 3.7 pM 30 s prior to the addition of PGLa. Time 0 indicates the 
addition time of PGLa. The mixture at a ratio of 1:20 PGLa to mgn2a 
is as active as a 23-fold higher concentration of PGLa alone. 
for apolipoprotein A-I  (Brouillette et al., 1982). 
We added ribonuclease S-peptide to DPPG liposomes to 
provide a comparison of our results with mgn2a with the 
liposome binding behavior of another positively charged peptide 
of about the same size as mgn2a, but with much lower helix 
hydrophobic moment and fewer hydrophobic residues. Ri- 
bonuclease S-peptide copellets with DPPG liposomes in an 
unfolded or random structure (Table I) and disrupts the lipid 
acyl chains of gel-phase DPPG more than either mgn2a or 
melittin. Because the S-peptide is not helical in this mem- 
brane-bound state, we suspect that this interaction is mainly 
electrostatic and that penetration of the hydrophobic acyl-chain 
region of the bilayer is minimal. This suggests that peptide 
structures other than helix can significantly disrupt lipid bi- 
layers, changing their permeability and surface area. 
PGLa Structure. PGLa is less soluble in aqueous solutions 
than is mgn2a, reversibly forming a precipitate in saline at pH 
7.4 and low temperatures that contains @-sheet and reverse 
turn structure. It forms a mostly unfolded structure in water 
at pH 3.2, in saline at pH 7.4, and at  ambient temperatures 
(Figure 4A; Table I). PGLa forms a /3-sheet structure in water 
at neutral pH, probably in an aggregated form, although these 
solutions are clear. Upon binding to DPPG, PGLa shows an 
amide I band similar to that observed for the precipitated form. 
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